medigraphic.com
ISSN 0035-0052 (Print)

2013, Number 4

<< Back Next >>

Rev Mex Pediatr 2013; 80 (4)

Endothelins [ET] in arterial hypertension

Carbajal RL, Rodríguez HR, Zarco RJ, Perea MA, Copto GA

Language: Spanish
References: 31
Page: 150-153
PDF size: 96.67 Kb.


ABSTRACT

Of the group of vasoactive substances in the organism, the endothelins seem to have special importance in the physiology of cardiovascular diseases. Of these, the most studied is Et1. It is an autochrine hormone that could increase arterial pressure for being a powerful vasoconstrictor which is 100 times higher than the norepinephrin and 10 times higher than the angiotensin II. It is synthesized in the vascular endothelium and the smooth muscle. It is activated by vasoactive substances, hypoxia and vascular stress. The endothelins participate as modulators of vascular tone, celular proliferation and hormonal production. There are three kinds of Et: Et1, Et2, and Et3. The receptors of these kinds of Et3 are two: Eta and Etb. These receptors have three isoforms of endothelin converting enzymes as ECE1a, ECE1b and ECE1c. In the face of endothelial dysfunction due to risk factors the vasoconstriction functions are activated especially the Et1.


REFERENCES

  1. Yanawisaga M, Kirihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endotelial cells. Nature. 1998; 332: 411-415.

  2. Omland T, Lie RT, Aakvaag A. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation. 1994; 89: 1573-1579.

  3. Lerman A, Zeither MZ. Endothelial function: cardiac events. Circulation. 2005; 111: 363-368.

  4. Sakurai T, Yanawisawa M, Takuma Y. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990; 348: 732-735.

  5. Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989; 86: 2864-2867.

  6. Ellis RL. Endothelins. N Engl J Med. 1995; 333: 356-363.

  7. Giannessi D, del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res. 2001; 43: 111-126.

  8. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992; 10: 1379-1386.

  9. Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992; 90: 1023-1031.

  10. Levin ER. Endothelins. N Engl J Med. 1995; 333: 356-363.

  11. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61: 227-237.

  12. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990; 323: 27-36.

  13. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta; inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990; 85: 587-590.

  14. Prins BA, Hu RM, Nazario B. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endotelial cells. J Biol Chem. 1994; 269: 11938-11944.

  15. Morawietz H, Talanow R, Szibor M. Regulation of the endothelin system by shear stress in human endotelial cells. J Physiol. 2000; 525: 761-770.

  16. Balakrishnan SM, Wang HD, Gopalakrishnan V, Wilson TW, McNeill JR. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension. 1996; 28: 806-809.

  17. Pérez del Villar C, García ACJ, Feldstein CA, Juncos LA, Romero JC. Role of endothelin in the pathogenesis of hypertension. Clin Proc Mayo. 2005; 80: 84-96.

  18. Ergul A. Endothelin-1 and endothelin receptor antagonist as potential cardiovascular therapeutic agents. Pharmacotherapy. 2002; 221: 54-65.

  19. Dupuis J, Jasmin JF, Prie S, Cernacek P. Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther. 2000; 13: 135-140.

  20. Lerman A, Edwards BS, Hallet JW, Heublein DM, Sanberg SM, Burnett JC. Circulating and tissue endothelin inmunoreactivity in advanced aterosclerosis. N Engl J Med. 1991; 325: 997-1001.

  21. Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol. 2000; 35: S69-S73.

  22. Cardillo C, Kilcoyne C, Cannon RIII, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000; 35: 1237-1242.

  23. Fennesy FM, Moneley DS, Wang JH, Kelly CJ, Bouchier-Hayes DJ. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation. 2003; 107: 410-415.

  24. Cardillo C, Nambi SS, Kilcoyne CM, Choucair KW, Katz A, Quon MJ. Insulin simulates both endothelin and nitric oxide activity in the human foream. Circulation. 1999; 100: 820-825.

  25. Gomezgarre D, Ruizortega M, Ortego M, Largo R, Lopezarmada MJ, Plaza JJ. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and mesangial cell growth. Hypertension. 1996; 27: 885-892.

  26. Josko J, Gwozdz B, Hendryk S, Jedrzejowska-Szypulka H. Expression of vascular endotelial growth factor (VEGF) in rat brain after subarachnoid haemorrhage and endothelin receptor blockade with BQ-123. Folia Neuropathol. 2001; 39: 243-251.

  27. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res. 2001; 2: 90-101.

  28. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular response to endothelin in the rat kidney. J Clin Invest. 1989; 83: 336-342.

  29. Marfin PY, Schriver RW. Sodium and Water retention in heart failure: pathogenesis and treatment. Kidney Int Supwl. 1997; 59: 57-61.

  30. Baltazares LM, Rodríguez CH, Ortega MJ, Sotves VA, Baltazares EM. Sistema endotelina. Rev Inst Nal Enf Resp Mex. 2005; 18: 308-320.

  31. Férez SAM. Lupi HE. El comportamiento del miocardio en la isquemia y en la reperfusión. Madrid Elsevier, Edición Conmemorativa 60 Aniversario 2004; p 450.




2020     |     www.medigraphic.com